[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Immunology](https://durgical.com/en/immunology/) › [Transplant, tumors and immunotherapy](https://durgical.com/en/immunology/areas/transplant/) › Graft-versus-host disease: the immunology

# Graft-versus-host disease: the immunology

- Process

After a donor stem cell transplant, donor immune cells can attack the patient's skin, [liver](https://durgical.com/en/anatomy/liver/) and gut.

Updated Nov 15, 2026

**See it in 3D:** [Skin](https://durgical.com/en/anatomy/skin/) · [Liver](https://durgical.com/en/anatomy/liver/)

## Key points

- Three requirements: the graft contains immunocompetent T cells, the host cannot reject them, and donor and host differ in HLA or minor antigens.
- Acute GVHD: maculopapular rash (often palms and soles), cholestatic [liver injury](https://durgical.com/en/conditions/liver-injury/) with jaundice, and watery or bloody diarrhea.
- Chronic GVHD: [scleroderma](https://durgical.com/en/conditions/systemic-sclerosis/) -like skin, [dry eyes](https://durgical.com/en/conditions/dry-eye-disease/) and mouth, [lichen planus](https://durgical.com/en/conditions/lichen-planus/) -like mouth lesions, [bronchiolitis](https://durgical.com/en/conditions/bronchiolitis/) obliterans, joint stiffness.
- Does not occur after autologous transplant (own cells).
- Transfusion-associated GVHD is rare but usually fatal; it is prevented by irradiating blood products for at-risk patients.
- The same donor T cells also attack residual leukemia: the graft-versus-leukemia effect.

## What it is

[Graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/) (GVHD) is the reverse of rejection: immunocompetent donor T cells recognize the recipient's tissues as foreign. It occurs mainly after allogeneic hematopoietic stem cell transplant, less often after liver or small bowel transplant or transfusion of non-irradiated blood. Acute GVHD targets the skin, liver and gut; chronic GVHD looks like an autoimmune disease affecting many organs.

## How to think about it

Rejection is the host attacking the guest; GVHD is the guest attacking the host. It needs a guest with working T cells, a host too weak to destroy them, and enough difference between the two. The first targets are the tissues already injured by conditioning and full of host antigen-presenting cells: skin, liver and gut.

## Key facts

- Risk is lower with well-matched related donors and higher with unrelated or mismatched donors.
- Prevention uses immunosuppressive drugs after transplant (for example a calcineurin inhibitor with [methotrexate](https://durgical.com/en/pharmacology/methotrexate/)) and, in some protocols, post-transplant [cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/) or T-cell depletion.
- [Corticosteroids](https://durgical.com/en/pharmacology/classes/corticosteroids/) are the first-line treatment for established GVHD.
- Acute and chronic forms are now told apart by their features rather than only by the old 100-day cut-off.

## Step by step

- Conditioning chemotherapy or radiation damages host tissues, especially the gut lining.
- Damaged tissue releases inflammatory cytokines ([TNF-α](https://durgical.com/en/immunology/tnf/), IL-1, IL-6) and microbial products.
- Host antigen-presenting cells activate donor T cells that recognize host HLA or minor antigens.
- Donor T cells expand and release [IL-2](https://durgical.com/en/pharmacology/aldesleukin/) and interferon-gamma.
- Cytotoxic T cells and cytokines damage the skin, bile ducts and intestinal epithelium.

## Rejection or GVHD: who attacks whom

| Feature | Transplant rejection | Graft-versus-host disease |
| --- | --- | --- |
| Who attacks | Recipient immune cells attack the graft | Donor T cells attack the recipient |
| Typical setting | Solid organ (kidney, heart, lung, liver) | Allogeneic stem cell transplant; rarely liver or bowel graft, non-irradiated blood |
| What is damaged | The transplanted organ only | Skin, liver (bile ducts) and gut; many organs in the chronic form |
| Prevention | ABO and HLA [matching](https://durgical.com/en/epidemiology/matching/), crossmatch, immunosuppression | HLA matching, immunosuppression after transplant, T-cell depletion, irradiated blood |
| Hidden benefit | None | Graft-versus-leukemia effect |

## Common traps

- **GVHD is a form of transplant rejection**: it runs the other way, with donor T cells attacking the patient instead of the patient attacking the graft.
- **Autologous stem cell transplants carry a GVHD risk**: the cells are the patient's own, so they find nothing foreign to attack.
- **Only an HLA mismatch causes GVHD**: minor histocompatibility antigens can trigger it even between HLA-identical siblings.
- **Removing every donor T cell is the ideal prevention**: it lowers GVHD but loses the graft-versus-leukemia effect and raises relapse and [graft failure](https://durgical.com/en/conditions/skin-grafts-and-flaps-covering-a-wound/).
- **Leukoreduced blood is enough to prevent transfusion-associated GVHD**: irradiation reliably stops donor lymphocytes from dividing (for platelets, pathogen reduction is considered equivalent).

## Test yourself

Think of the answer, then tap the question to see it.

## Which three organs are the main targets of acute graft-versus-host disease?

The skin (rash), liver (cholestatic jaundice) and gastrointestinal tract (diarrhea).

## Why does graft-versus-host disease not occur after an autologous transplant?

The cells are the patient's own, so they do not see the host tissues as foreign.

## How is transfusion-associated graft-versus-host disease prevented?

By irradiating cellular blood products for at-risk recipients, which stops donor lymphocytes from dividing.

## What benefit can donor T cells provide after a transplant for leukemia?

The graft-versus-leukemia effect: they attack remaining leukemia cells.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/immunology/graft-versus-host-disease-the-immunology/)

## Connections

## See it in 3D 2

The structures of Durgical's 3D anatomy where it is found.

- [Skin](https://durgical.com/en/anatomy/skin/)
- [Liver](https://durgical.com/en/anatomy/liver/)

## Related 5

- [Transfusion reactions: the immunology](https://durgical.com/en/immunology/transfusion-reactions-the-immunology/)
- [MHC/HLA class I and II](https://durgical.com/en/immunology/mhc-hla-class-i-and-ii/)
- [CD8⁺ cytotoxic T cell](https://durgical.com/en/immunology/cd8-cytotoxic-t-cell/)
- [Transplant rejection: hyperacute, acute, chronic](https://durgical.com/en/immunology/transplant-rejection-hyperacute-acute-chronic/)
- [Immunosuppressants by mechanism (classes)](https://durgical.com/en/immunology/immunosuppressants-by-mechanism/)

## In Pharmacology 2

- [Methotrexate](https://durgical.com/en/pharmacology/methotrexate/)
- [Tacrolimus](https://durgical.com/en/pharmacology/tacrolimus/)

[← All of immunology](https://durgical.com/en/immunology/)

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: [Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review](https://europepmc.org/article/PMC/PMC11086996) (Clinical Hematology International (Europe PMC open access), 2024); [Graft-versus-host disease](https://medlineplus.gov/ency/article/001309.htm) (MedlinePlus, U.S. National Library of Medicine, 2026); [Transplant rejection](https://medlineplus.gov/ency/article/000815.htm) (MedlinePlus, U.S. National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/immunology/graft-versus-host-disease-the-immunology/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/immunology/graft-versus-host-disease-the-immunology/
